Thyroid carcinoma, version 2.2014: Featured updates to the NCCN guidelines

R. Michael Tuttle; Robert I. Haddad; Douglas W. Ball; David Byrd; Paxton Dickson; Quan Yang Duh; Hormoz Ehya; Megan Haymart; Carl Hoh; Jason P. Hunt; Andrei Iagaru; Fouad Kandeel; Peter Kopp; Dominick M. Lamonica; William M. Lydiatt; Judith McCaffrey; Jeffrey F. Moley; Lee Parks; Christopher D. Raeburn; John A. Ridge; Matthew D. Ringel; Randall P. Scheri; Jatin P. Shah; Steven I. Sherman; Cord Sturgeon; Steven G. Waguespack; Thomas N. Wang; Lori J. Wirth; Karin G. Hoffmann; Miranda Hughes

doi:10.6004/jnccn.2014.0169

Thyroid carcinoma, version 2.2014: Featured updates to the NCCN guidelines

R. Michael Tuttle, Robert I. Haddad, Douglas W. Ball, David Byrd, Paxton Dickson, Quan Yang Duh, Hormoz Ehya, Megan Haymart, Carl Hoh, Jason P. Hunt, Andrei Iagaru, Fouad Kandeel, Peter Kopp, Dominick M. Lamonica, William M. Lydiatt, Judith McCaffrey, Jeffrey F. Moley, Lee Parks, Christopher D. Raeburn, John A. RidgeMatthew D. Ringel, Randall P. Scheri, Jatin P. Shah, Steven I. Sherman, Cord Sturgeon, Steven G. Waguespack, Thomas N. Wang, Lori J. Wirth, Karin G. Hoffmann, Miranda Hughes

School of Medicine

Research output: Contribution to journal › Article › peer-review

104 Scopus citations

Abstract

These NCCN Guidelines Insights focus on some of the major updates to the 2014 NCCN Guidelines for Thyroid Carcinoma. Kinase inhibitor therapy may be used to treat thyroid carcinoma that is symptomatic and/or progressive and not amenable to treatment with radioactive iodine. Sorafenib may be considered for select patients with metastatic differentiated thyroid carcinoma, whereas vandetanib or cabozantinib may be recommended for select patients with metastatic medullary thyroid carcinoma. Other kinase inhibitors may be considered for select patients with either type of thyroid carcinoma. A new section on "Principles of Kinase Inhibitor Therapy in Advanced Thyroid Cancer" was added to the NCCN Guidelines to assist with using these novel targeted agents.

Original language	English (US)
Pages (from-to)	1671-1680
Number of pages	10
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	12
Issue number	12
DOIs	https://doi.org/10.6004/jnccn.2014.0169
State	Published - Dec 1 2014

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2014.0169

Cite this

Tuttle, R. M., Haddad, R. I., Ball, D. W., Byrd, D., Dickson, P., Duh, Q. Y., Ehya, H., Haymart, M., Hoh, C., Hunt, J. P., Iagaru, A., Kandeel, F., Kopp, P., Lamonica, D. M., Lydiatt, W. M., McCaffrey, J., Moley, J. F., Parks, L., Raeburn, C. D., ... Hughes, M. (2014). Thyroid carcinoma, version 2.2014: Featured updates to the NCCN guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 12(12), 1671-1680. https://doi.org/10.6004/jnccn.2014.0169

Tuttle, RM, Haddad, RI, Ball, DW, Byrd, D, Dickson, P, Duh, QY, Ehya, H, Haymart, M, Hoh, C, Hunt, JP, Iagaru, A, Kandeel, F, Kopp, P, Lamonica, DM, Lydiatt, WM, McCaffrey, J, Moley, JF, Parks, L, Raeburn, CD, Ridge, JA, Ringel, MD, Scheri, RP, Shah, JP, Sherman, SI, Sturgeon, C, Waguespack, SG, Wang, TN, Wirth, LJ, Hoffmann, KG & Hughes, M 2014, 'Thyroid carcinoma, version 2.2014: Featured updates to the NCCN guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 12, no. 12, pp. 1671-1680. https://doi.org/10.6004/jnccn.2014.0169

@article{64fed023d308430cbcb0f87eb3f89cb2,

title = "Thyroid carcinoma, version 2.2014: Featured updates to the NCCN guidelines",

abstract = "These NCCN Guidelines Insights focus on some of the major updates to the 2014 NCCN Guidelines for Thyroid Carcinoma. Kinase inhibitor therapy may be used to treat thyroid carcinoma that is symptomatic and/or progressive and not amenable to treatment with radioactive iodine. Sorafenib may be considered for select patients with metastatic differentiated thyroid carcinoma, whereas vandetanib or cabozantinib may be recommended for select patients with metastatic medullary thyroid carcinoma. Other kinase inhibitors may be considered for select patients with either type of thyroid carcinoma. A new section on {"}Principles of Kinase Inhibitor Therapy in Advanced Thyroid Cancer{"} was added to the NCCN Guidelines to assist with using these novel targeted agents.",

author = "Tuttle, {R. Michael} and Haddad, {Robert I.} and Ball, {Douglas W.} and David Byrd and Paxton Dickson and Duh, {Quan Yang} and Hormoz Ehya and Megan Haymart and Carl Hoh and Hunt, {Jason P.} and Andrei Iagaru and Fouad Kandeel and Peter Kopp and Lamonica, {Dominick M.} and Lydiatt, {William M.} and Judith McCaffrey and Moley, {Jeffrey F.} and Lee Parks and Raeburn, {Christopher D.} and Ridge, {John A.} and Ringel, {Matthew D.} and Scheri, {Randall P.} and Shah, {Jatin P.} and Sherman, {Steven I.} and Cord Sturgeon and Waguespack, {Steven G.} and Wang, {Thomas N.} and Wirth, {Lori J.} and Hoffmann, {Karin G.} and Miranda Hughes",

note = "Publisher Copyright: {\textcopyright} JNCCN-Journal of the National Comprehensive Cancer Network.",

year = "2014",

month = dec,

day = "1",

doi = "10.6004/jnccn.2014.0169",

language = "English (US)",

volume = "12",

pages = "1671--1680",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "12",

}

TY - JOUR

T1 - Thyroid carcinoma, version 2.2014

T2 - Featured updates to the NCCN guidelines

AU - Tuttle, R. Michael

AU - Haddad, Robert I.

AU - Ball, Douglas W.

AU - Byrd, David

AU - Dickson, Paxton

AU - Duh, Quan Yang

AU - Ehya, Hormoz

AU - Haymart, Megan

AU - Hoh, Carl

AU - Hunt, Jason P.

AU - Iagaru, Andrei

AU - Kandeel, Fouad

AU - Kopp, Peter

AU - Lamonica, Dominick M.

AU - Lydiatt, William M.

AU - McCaffrey, Judith

AU - Moley, Jeffrey F.

AU - Parks, Lee

AU - Raeburn, Christopher D.

AU - Ridge, John A.

AU - Ringel, Matthew D.

AU - Scheri, Randall P.

AU - Shah, Jatin P.

AU - Sherman, Steven I.

AU - Sturgeon, Cord

AU - Waguespack, Steven G.

AU - Wang, Thomas N.

AU - Wirth, Lori J.

AU - Hoffmann, Karin G.

AU - Hughes, Miranda

PY - 2014/12/1

Y1 - 2014/12/1

N2 - These NCCN Guidelines Insights focus on some of the major updates to the 2014 NCCN Guidelines for Thyroid Carcinoma. Kinase inhibitor therapy may be used to treat thyroid carcinoma that is symptomatic and/or progressive and not amenable to treatment with radioactive iodine. Sorafenib may be considered for select patients with metastatic differentiated thyroid carcinoma, whereas vandetanib or cabozantinib may be recommended for select patients with metastatic medullary thyroid carcinoma. Other kinase inhibitors may be considered for select patients with either type of thyroid carcinoma. A new section on "Principles of Kinase Inhibitor Therapy in Advanced Thyroid Cancer" was added to the NCCN Guidelines to assist with using these novel targeted agents.

AB - These NCCN Guidelines Insights focus on some of the major updates to the 2014 NCCN Guidelines for Thyroid Carcinoma. Kinase inhibitor therapy may be used to treat thyroid carcinoma that is symptomatic and/or progressive and not amenable to treatment with radioactive iodine. Sorafenib may be considered for select patients with metastatic differentiated thyroid carcinoma, whereas vandetanib or cabozantinib may be recommended for select patients with metastatic medullary thyroid carcinoma. Other kinase inhibitors may be considered for select patients with either type of thyroid carcinoma. A new section on "Principles of Kinase Inhibitor Therapy in Advanced Thyroid Cancer" was added to the NCCN Guidelines to assist with using these novel targeted agents.

UR - http://www.scopus.com/inward/record.url?scp=84918790948&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84918790948&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2014.0169

DO - 10.6004/jnccn.2014.0169

M3 - Article

C2 - 25505208

AN - SCOPUS:84918790948

SN - 1540-1405

VL - 12

SP - 1671

EP - 1680

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 12

ER -

Thyroid carcinoma, version 2.2014: Featured updates to the NCCN guidelines

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this